司美格鲁肽或可降低双相情感障碍患者精神住院风险

格里菲斯大学的研究人员发现，司美格鲁肽（Ozempic和Wegovy的活性成分）与双相情感障碍患者精神住院风险降低21%存在关联。1这项历时15年的大规模研究涵盖瑞典近15000名双相情感障碍患者，时间跨度从2009年至2024年，表明GLP-1类药物可能具有超越糖尿病和肥胖治疗范畴的心理健康益处。1全球约有3700万人患有双相情感障碍，占全球人口的约1/200。1

研究团队认为，GLP-1信号可能通过减少炎症和细胞应激来保护大脑。1值得注意的是，其他GLP-1药物利拉格鲁肽和度拉糖肽并未显示相同的精神住院风险降低模式。1研究人员建议进行随机对照试验以获得更强有力的证据，进一步验证这一发现。1

Researchers at Griffith University have identified a potential psychiatric advantage of semaglutide, the active ingredient in the diabetes and weight-loss medications Ozempic and Wegovy.1 The large-scale study, conducted across Sweden and spanning 15 years, found that semaglutide use was associated with a 21 percent reduction in the risk of psychiatric hospitalization among patients with bipolar disorder.1 The research examined nearly 15,000 Swedish individuals with bipolar disorder between 2009 and 2024.1

The findings suggest that GLP-1 receptor agonists may confer mental health benefits beyond their established roles in treating diabetes and obesity.1 Professor Mark Taylor proposed that GLP-1 signaling may protect the brain by reducing inflammation and cellular stress.1 However, the mental health advantage appears specific to semaglutide; other GLP-1 medications, including liraglutide and dulaglutide, did not demonstrate the same pattern of reduced psychiatric hospitalization risk.1 Bipolar disorder affects approximately 37 million people globally, representing roughly 1 in 200 of the world's population.1 The research team has called for randomized controlled trials to establish more robust evidence for these preliminary findings.1